Norwich Fills Top Spots With Eye Toward Future Growth
Norwich Pharmaceuticals, Inc. recently announced the appointment of Douglas L. Drysdale to the newly created position of Chief Executive Officer, and added top talent in two growth areas as the company looks to expand its contract manufacturing and packaging services.
Mr. Drysdale most recently served as VP, Mergers & Acquisitions for Actavis Group hf. He previously held positions at Alpharma, Inc. as VP, Global Business Development, and at Forest Laboratories, Inc. Drysdale earned his degree in Microbial and Molecular Biology from the University of East Anglia, UK, and has been the driving force behind over 100 pharmaceutical and biotech transactions.
Christopher R. Calhoun, who will continue serving as president of Norwich Pharmaceuticals, announced, "We are very excited to have someone of Doug's caliber as our CEO. His in-depth pharmaceutical experience will help Norwich accelerate its current rate of growth, while remaining true to the high standards of quality and uncommon value that the industry has come to expect from us."
The two additional appointees were Thomas Salus and Robert Klehr. Both have held managerial and sales positions within the pharmaceutical outsourcing industry, and both will be responsible for new business development. They will be based in New Jersey and will share responsibility for covering the continental U.S. Tom and Bob will be instrumental in driving the accelerated growth that Norwich has planned for the future.
Tom Salus most recently applied his business development experience on behalf of Glatt Pharmaceutical Services. Prior to Glatt, Tom spent time with Banner Pharmacaps and AAI Inc. He is a graduate of West Chester University with a BS in Forensic Chemistry, and is a member of the American Association of Pharmaceuticals.
Bob Klehr joins Norwich after serving as Director of Business Development for DPT Laboratories. Prior to DPT, Bob spent time with Patheon and Fisher Scientific Company. Bob attended Rochester Institute of Technology and St. John Fisher. He is a member of the American Association of Pharmaceuticals, American Chemical Society, and Parenteral Drug Association.
Norwich will be making future capital investments in its business to support the growth plan it has in place. In 2008, Norwich will add a new packaging line, a capsule bander, and two Bosch 1500 encapsulators.
Based in Norwich, NY, Norwich Pharmaceuticals, Inc. is an outsourcing pharmaceutical manufacturing and packaging provider. The company services the pharmaceutical industry exclusively, providing comprehensive support - from clinical trials, through scale-up, to commercial launch - to marketers of solid dose, semi-solid, and liquid pharmaceutical products. For over 120 years, the Norwich facility has played a role in the pharmaceutical industry. Company services include: outsourced manufacturing, packaging, laboratory services, and distribution.
